Showing results (321-330 of 7,002) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|December 24, 2013
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutationLiza C Villaruz, Mark A Socinski
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerBing Li, Shengxiang Ren, Xuefei Li, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancerJean-Louis Pujol, Robert Pirker, Thomas J Lynch, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2013
Outcome of surgically resected thymic carcinoma: a multicenter experiencePier Luigi Filosso, Francesco Guerrera, Angelo Erino Rendina, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2021
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 studyD S-W Tan, M Thomas, D-W Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|January 18, 2022
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest GroupSamuel G Armato, Anna K Nowak, Roslyn J Francis, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2021
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLCD Rodríguez-Abreu, M Cobo, S García-Román, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2022
Which will carry more weight when CTR > 0.5, solid component size, CTR, tumor size or SUVmax?Shaoyuan Zhang, Dong Lin, Yangli Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2022
TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical dataAnn-Katrine Jakobsen, Sakineh Yuusufi, Line Bille Madsen, et al.
Pageof 701